フクヤマ先天性筋縮症:臨床的特徴と治療の進歩

Keiko Ishigaki¹, Mariko Taniguchi-Ikeda²

¹Department of Pediatrics, Tokyo Women's Medical University, School of Medicine, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

Brain & development

|September 6, 2025

まとめ

フクヤマ先天性筋縮症 (FCMD) は,治療法のない重症の遺伝疾患である. スプライシングの欠陥を標的とした有望な治療法や前薬のアプローチは臨床試験中であり患者に新しい希望を与えています

科学分野:

遺伝学
神経学
生物化学

背景:

フクヤマ先天性筋縮症 (FCMD) は,主に日本人に影響する深刻な遺伝疾患です.
FCMDは脳と目の異常で重度の障害と早期死亡に繋がります
現在,FCMDの最終的な治療法は存在しない.

研究の目的:

FCMDの臨床経過をレビューする.
FCMDの新興治療戦略の概要を提示する.
FCMDの治療開発における最近の進歩を強調する.

主な方法:

FCMDに関する臨床データと研究のレビュー
遺伝的基礎の分析:FKTN遺伝子に3kbのSVAレトロトランポゾン挿入
O-マノシルグリコシル化におけるFKTN遺伝子産物の役割の調査

主要な成果:

FCMDは,FKTNのレトロトランポゾン挿入によるスプライシング障害によって引き起こされます.
アンチセンセスの核酸を用いたスプライシング・モジュレーション・セラピーが臨床試験中です
グリコシルトランスフェラーゼとしてのFKTNの役割は,前薬療法の可能性を示唆する.
ステロイドは予備試験で有効性が示され,現在第2相試験が進行中です.

結論:

FCMDの治療には,スプライシング・モジュレーションとプロドラッグを含む新たな治療法が有望である.
現在進行中の臨床試験は効果的な治療法と保険の承認を目的としています
FKTNの機能に関するさらなる研究は,FCMDの新たな治療法を開く可能性があります.

キーワード:

アルファ・ジストログリコパシーエクソン捕獲 FKTN フクヤマ先天性筋縮症レトロトランスポーソン

さらに関連する動画

09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.5K

10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.8K

関連する概念動画

01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

2.0K

01:28

Disorders of the Skeletal Muscle

1.1K

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

1.1K

01:20

Myasthenia Gravis: Overview and Treatment

1.9K

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

1.9K

01:24

Cystic Fibrosis: Management

220

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

220

01:15

Myasthenia Gravis: Diagnostic Tests

1.3K

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

1.3K

01:23

Cystic Fibrosis: Pathogenesis

358

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

358

関連する実験動画